DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

MEDP·Medpace Holdings, Inc.

$.
+. (+.%)
After Hours
High
$540.37
Open
$536.31
Market Cap
15.38B
52W High
$628.92
Low
$530.06
P. Close
$537.69
P/E
33.41
52W Low
$306.70
Fwd P/E
28.54
DailyIQ Est.
$457.96
Technical Score (1D)
91
BUY
News Sentiment
65
BULLISH
MEDP’s shares surged roughly 16% over the past month, lifting the stock above most analyst targets while still trading below several intrinsic‑value models, a move that has reignited debate over whether the market is overly cautious or overvalued. The rally has prompted investors to revisit valuation assumptions, as the company’s 1‑year total shareholder return of 66% and 5‑year return of 194% underscore its long‑term growth potential. Because the price now sits above consensus multiples, any forthcoming earnings guidance that deviates from expectations could quickly shift the valuation narrative. A modest earnings beat could reinforce the bullish case, while a miss might trigger a re‑downgrade of the stock’s valuation. The company’s clinical pipeline remains a key driver; updates on upcoming trial milestones or regulatory approvals could serve as catalysts for further price movement. Analysts are also watching for any changes in the company’s valuation metrics, such as adjusted EBITDA or free‑cash‑flow multiples, which could alter the perceived upside. Market sentiment remains cautious, with the stock still trading below some intrinsic‑value estimates, suggesting that volatility could persist in the next 1–10 trading days. Traders should keep an eye on the next earnings release for guidance on revenue growth and margin expectations. Additionally, any news regarding regulatory decisions or clinical trial results in the coming days could provide the next decisive factor for the stock’s trajectory.
Earnings Summary
Medpace Holdings, Inc. is a clinical research organization that delivers end‑to‑end drug and medical device development services across North America, Europe, and Asia, positioning itself as a full‑service partner for pharmaceutical, biotechnology, and medical device companies. In the healthcare diagnostics & research sector, Medpace’s integrated offerings—including trial design, regulatory affairs, data analysis, and specialized central laboratory services—enable it to capture a broad client base. In Q4 2024 the company reported EPS of $3.68 versus an estimate of $3.12 and revenue of $536.6 million, while in Q4 2025 EPS rose to $4.67 against an estimate of $4.23 and revenue climbed to $708.5 million, a 32.9 % year‑over‑year increase that also beat the $690.9 million estimate; the firm has thus beaten analyst expectations in both recent quarters. Historically, Medpace has shown a consistent upward trajectory in both revenue and earnings, with YoY growth rates hovering in the mid‑20s to low‑30s percent range and a pattern of earnings beats even when revenue growth slows, suggesting resilient profitability. Recent news highlights a 16 % share rally that has pushed the stock above many analyst targets, yet a series of downgrades from Baird, Jefferies, and others citing slowing revenue growth and margin pressure has tempered sentiment; the company’s pipeline updates and regulatory approvals remain key catalysts for price movement. Investors should watch the next earnings release for guidance on revenue projections, margin expectations, backlog composition, and cancellation trends, as well as any regulatory announcements that could lift the pipeline, because these factors will shape the valuation narrative in the coming weeks.

EPS

EstBeatMiss
$2.88$3.39$3.89$4.40$4.90Q4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$4.00 - -
Q4'25$4.23$4.67+10.5%
Q4'24$3.12$3.68+18.1%

Revenue

EstBeatMiss
$511M$567M$623M$678M$734MQ4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$703M - -
Q4'25$691M$708M+2.5%
Q4'24 - $537M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MEDP Stock Snapshot

MEDP is currently trading at $538.23, giving Medpace Holdings, Inc. a market cap of 15.38B and a P/E ratio of 33.4. Today's range spans $530.06–$540.37, with shares opening at $536.31 and moving up $0.54 (0.1%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 65/100.

Over the past year MEDP has traded between $306.70 and $628.92 - the current price is +75.5% off the 52-week low and -14.4% from the high. 21 analysts cover the stock with a Hold consensus and a mean 12-month target of $451.42 (range $329.00–$547.00), implying downside of -16.1%.

Relative strength is the story for Medpace Holdings, Inc. (MEDP) in Healthcare right now. Technical score 91/100 (BUY), sentiment bullish at 65/100, price $538.23 (in the upper portion of its 52-week range). The current P/E ratio stands at 33.4. The 15.38B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $306.70–$628.92.

The combination of a BUY signal (91/100) and bullish news sentiment (65/100) puts MEDP on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 15.38B in Healthcare market cap without immediately moving the stock. At $538.23 (in the upper portion of its 52-week range in the $306.70–$628.92 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.